Brand Spotlight: The Science Behind FILLMED® Laboratories

FILLMED® Laboratories, also known as Laboratoires FILLMED®, is the Paris-based aesthetic medicine company behind the FILLMED® brand. Its activities include developing, manufacturing, and distributing injectable and skincare products for medical professionals. In this spotlight, Doctor Medica looks at FILLMED® Laboratories as a company: where it came from, the science behind FILLMED® skin perfusion and its injectables, and how it sits in today’s aesthetics market.

This article will explore the company’s history and ownership, its core technologies, how it formulates and manufactures, and where it sells. For clinics that already buy FILLMED® online, knowing the company behind the labels helps when weighing its clinical claims, regulatory standing, and long-term supply.

Key Takeaways

• FILLMED® traces its origins to 1978, when Dr. Michel Tordjman founded the laboratory and created the NCTF® revitalizing solution.
• The medical business separated from Filorga’s consumer cosmetics arm in 2015 and is backed by investment group HLD; Colgate-Palmolive bought only the cosmetics side in 2019.
• FILLMED® is distributed in over 80 countries, and its investor credits the company with more than half of the global mesotherapy segment.

About: Doctor Medica is your trusted supplier of top-quality dermal fillers, viscosupplements, and more for your medical practice. We offer genuine products from leading brands at the lowest prices in the market. If you’re looking to buy FILLMED® for your practice, contact Doctor Medica today.

Who Is FILLMED® Laboratories?

The origins of FILLMED® Laboratories date to 1978, when French aesthetic physician Dr. Michel Tordjman established the original laboratory and developed NCTF® (New Cellular Treatment Factor) [5]. His aim was to equip dermatologists and aesthetic doctors with a full toolkit of peels, hyaluronic acid injections, and biorevitalizing solutions [5].

The ownership story is where the FILLMED® and Filorga names are often confused. The timeline below untangles them.

Year	Milestone
1978	Laboratory founded by Dr. Michel Tordjman; NCTF® launched [5]
2010	HLD and Didier Tabary jointly take control of Laboratoires Filorga, then home to both a cosmetics and a medical business [4]
2013	SKIN PERFUSION range launched [5]
2015	Cosmetics (Filorga) and medical (FILLMED®) businesses split to pursue separate strategies [4]
2016	ART FILLER® range launched; FILLMED® enters the UK market, initially under the Filorga Medical name [5]
2019	Colgate-Palmolive acquires Laboratoires Filorga Cosmétiques, the consumer skincare business [3]
2025	NCTF® 135 HA (February) and the ART FILLER® range (October) receive EU MDR certification [5]

Today, Laboratoires FILLMED® remains headquartered in Paris and sits in HLD’s portfolio, with Alexandre Brennan as CEO and a workforce of 356 [4].

What Technology Powers FILLMED®’s Products?

FILLMED® builds its portfolio around regeneration, using what it calls a multilayer approach in which each product line targets a different layer of the skin [5]. Three technologies carry most of the science.

NCTF®: The Founding Formula

NCTF® 135 HA works in the dermis. It combines 59 active ingredients, drawn from groups such as vitamins, amino acids, and minerals, with non-cross-linked hyaluronic acid [5]. FILLMED® states that the recipe has stayed the same since 1978 [5]. In a randomized, controlled multicenter trial of 146 subjects, NCTF® 135 HA reduced superficial wrinkles on the face, neck, and décolleté and improved radiance compared with an anti-ageing cream alone [1].

Tri-Hyal®: Engineered Hyaluronic Acid

Tri-Hyal® is FILLMED®’s formulation technology for the ART FILLER® range, combining free hyaluronic acid with cross-linked HA chains of different lengths. The technology forms part of the company’s approach to developing injectables for different aesthetic indications [5].

SKIN PERFUSION: Topical Skincare Technology

SKIN PERFUSION is the physician-dispensed cosmeceutical line, designed for the epidermis and built on what FILLMED® describes as patented penetration science [5]. Its role is to prepare skin before procedures and support recovery afterwards, extending results at home [5].

Together, the three lines target signs of skin ageing from different angles: nourishment, structure, and surface. FILLMED® frames this as a “pro-ageing” philosophy focused on overall skin quality rather than altering features [5].

What Product Categories Does FILLMED® Laboratories Offer?

FILLMED® Laboratories operates across injectable aesthetics, mesotherapy, and professional skincare. Its established portfolio includes ART FILLER®, NCTF® 135 HA, and SKIN PERFUSION, while selected regional markets also feature products supplied through distribution partnerships [5].

• Hyaluronic acid fillers. ART FILLER® includes formulations developed for different facial indications, from fine-line correction to volume restoration [5].
• Mesotherapy. NCTF® 135 HA is the company’s polyrevitalizing solution for the dermis, sold alongside dedicated delivery needles [5].
• Collagen biostimulators. Through a distribution partnership with Korean manufacturer VAIM, FILLMED® has expanded its offering in selected markets to include JUVELOOK® and LENISNA®, which use PDLLA and hyaluronic acid technology.
• Advanced skin therapies. SKIN PERFUSION covers professional peels and take-home cosmeceuticals for pre- and post-procedure care [5].

This combination of injectable and topical product categories supports FILLMED®’s approach to treatment planning across different skin layers.

How Does FILLMED® Combine Its Technologies in Treatment Protocols?

FILLMED®’s multilayer approach extends beyond individual product formulations to the use of complementary treatments. Its BIONUTRILIFT protocol, for example, combines an HA-based filler using Tri-Hyal® technology with a skin biorevitalizer to address multiple signs of facial ageing [2]. This provides a practical example of how the company’s injectable technologies may be incorporated into a combined treatment plan.

FILLMED® describes NCTF® 135 HA as a cellular stimulator that can enhance and prolong the results of other aesthetic procedures [5]. A four-month multicenter study of a combined FILLMED® protocol supported this, reporting reductions of 61% in skin-radiance scores and 55% in cheek-fold wrinkle scores, with 96% and 77% of subjects improving by at least one point respectively [2].

These results come from a non-randomized, FILLMED®-sponsored study [2]. They describe improvements observed with the combined protocol but do not establish superiority over alternative treatment approaches.

What Is FILLMED®’s Approach to Manufacturing and Environmental Impact?

Manufacturing is where FILLMED® is most transparent. The company reports a custom-built production unit designed specifically for ART FILLER®, with every syringe inspected individually by hand and by eye [5]. Its published certifications include ISO 13485 for medical-device quality management, MDSAP, and EU MDR certification for both NCTF® 135 HA and the ART FILLER® range [5]. Each box also carries a QR code that practitioners can scan to verify authenticity [5].

Public information on environmental impact is narrower. The clearest documented example is the SMARTOUCH syringe, which uses one-third sustainable materials, including bioplastics and recycled plastics, and is reported to cut its carbon impact by 25.14%, or about 3.12 tonnes per year [6]. On the social side, FILLMED® partners with the French association Force Femmes [6].

FILLMED® does not appear to publish a full sustainability report, so clinics with formal procurement criteria may want to ask their distributor for further documentation.

How Popular Is FILLMED®, and Where Does It Operate?

FILLMED® has a substantial international presence in specialist aesthetic medicine. Its investor, HLD, reports turnover of €87 million, availability in at least 85 countries, and a market share exceeding 50% in the mesotherapy segment [4].

Key markets include France, where the company is based, and the UK, where it has operated since 2016 [5]. Its regional websites cover France, the UK, Poland, Italy, Spain, and Portugal [5], and FILLMED®’s recent activity log includes an Asia Masterclass in April 2026 alongside the IMCAS and AMWC congresses [5].

ART FILLER® joined FILLMED®’s portfolio in 2016, expanding the company’s established work in skin revitalization into a dedicated HA filler range [5]. Its aesthetic medicine offering also includes FILLMED® NANOSOFT® microneedles, marketed through a partnership with NanoPass Technologies for intradermal injection applications.

What Evidence Supports FILLMED®’s Industry Standing?

Industry recognition, as FILLMED® publishes it on its own expertise page, includes a Product of the Year award in 2021, Medical Education Awards in 2022 for its E-ACADEMY training platform, and a 2023 award naming NCTF® 135 HA best injectable skin revitalization product [5]. FILLMED®’s scientific committee includes dermatologists, a facial plastic surgeon, and aesthetic doctors from France, Italy, and South Africa [5].

These activities demonstrate FILLMED®’s involvement in professional education and industry events, although they do not establish a consensus of practitioner opinion.

The clinical studies cited in this article include manufacturer-funded research [1][2]. Their findings should therefore be considered alongside the study designs, comparison groups, and reported limitations rather than interpreted solely through headline outcome percentages.

Looking to buy FILLMED® products online? Get in touch with our customer service representatives at Doctor Medica for further guidance.

For licensed medical professionals only. This content is for informational purposes only and does not constitute medical advice.

Citations

[1] Fanian, Ferial et al. “A hyaluronic acid-based micro-filler improves superficial wrinkles and skin quality: a randomized prospective controlled multicenter study.” The Journal of dermatological treatment vol. 34,1 (2023): 2216323. doi:10.1080/09546634.2023.2216323

[2] Fanian, Ferial et al. “Evaluation of the Performance and Tolerance of the Combination of an HA-based Filler with Tri-Hyal Technology and a Skin Biorevitalizer on Skin Aging Parameters.” Clinical, cosmetic and investigational dermatology vol. 16 1095-1105. 24 Apr. 2023, doi:10.2147/CCID.S372490

[3] Colgate-Palmolive Company. “Form 10-K: Annual Report for the Fiscal Year Ended December 31, 2019.” U.S. Securities and Exchange Commission, filed 21 Feb. 2020, www.sec.gov/Archives/edgar/data/21665/000002166520000004/cl-12312019x10k.htm.

[4] HLD. “Fillmed.” HLD, groupehld.com/participations/fillmed.

[5] FILLMED. “Dermal Filler Experts & Anti-Aging Treatments.” FILLMED, fillmed.com/expertise/.

[6] HLD. “Laboratoires FillMed, a Committed Brand.” HLD, 3 May 2024, groupehld.com/en/news/laboratoires-fillmed-a-committed-brand.